| Literature DB >> 33275880 |
Li Gao1, Joyce C M Meiring2, Yvonne Kraus1, Maximilian Wranik3, Tobias Weinert3, Stefanie D Pritzl4, Rebekkah Bingham1, Evangelia Ntouliou1, Klara I Jansen2, Natacha Olieric3, Jörg Standfuss3, Lukas C Kapitein2, Theobald Lohmüller4, Julia Ahlfeld1, Anna Akhmanova2, Michel O Steinmetz5, Oliver Thorn-Seshold6.
Abstract
Optically controlled chemical reagents, termed "photopharmaceuticals," are powerful tools for precise spatiotemporal control of proteins particularly when genetic methods, such as knockouts or optogenetics are not viable options. However, current photopharmaceutical scaffolds, such as azobenzenes are intolerant of GFP/YFP imaging and are metabolically labile, posing severe limitations for biological use. We rationally designed a photoswitchable "SBT" scaffold to overcome these problems, then derivatized it to create exceptionally metabolically robust and fully GFP/YFP-orthogonal "SBTub" photopharmaceutical tubulin inhibitors. Lead compound SBTub3 allows temporally reversible, cell-precise, and even subcellularly precise photomodulation of microtubule dynamics, organization, and microtubule-dependent processes. By overcoming the previous limitations of microtubule photopharmaceuticals, SBTubs offer powerful applications in cell biology, and their robustness and druglikeness are favorable for intracellular biological control in in vivo applications. We furthermore expect that the robustness and imaging orthogonality of the SBT scaffold will inspire other derivatizations directed at extending the photocontrol of a range of other biological targets.Entities:
Keywords: antimitotic; azobenzene; cell cycle; cytoskeleton; microtubule dynamics; photochromismism; photopharmacology; photoswitch; spatiotemporal control; tubulin polymerization inhibitor
Year: 2020 PMID: 33275880 DOI: 10.1016/j.chembiol.2020.11.007
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116